When a dog owner asks, "Does my dog really need monthly parasite protection?"-the answer almost always comes back to understanding what the medication actually does inside the body. Afoxolaner and milbemycin oxime chewable tablets are among the most scientifically advanced combination antiparasitic products available for dogs today. They work through two separate but complementary biological pathways, targeting both external parasites like fleas and ticks and internal parasites like heartworms and gastrointestinal nematodes in a single monthly dose.
This article breaks down the pharmacological science behind the product in plain language, so you can understand exactly why it works-and why it has earned a strong reputation in veterinary medicine worldwide.
Afoxolaner And Milbemycin Oxime Chewable Tablets
1.General Specification(in stock)
(1)API(Pure powder)
(2)Tablet
9.375+1.875mg：2-3.5kg
18.75+3.75mg：＞3.5-7.5kg
37.5+7.5mg：＞7.5-15kg
75+15mg：＞15-30kg
150+30mg：＞30-60kg
(3)Ointment
2.Customization:
We will negotiate individually, OEM/ODM, No brand, for secience researching only.
Internal Code: BM-2-117
Main market: USA, Australia, Brazil, Japan, Germany, Indonesia, UK, New Zealand , Canada etc.
Manufacturer: BLOOM TECH Xi'an Factory
What Is the Dual Mechanism of Afoxolaner and Milbemycin Oxime Chewable Tablets?
Two Active Ingredients, One Comprehensive Formula
The mixture has two different medicines that work together: afoxolaner and milbemycin oxime. There are different kinds of drugs, and each one uses a different set of chemicals to kill a certain type of bug. Afoxolaner is an isoxazoline, which means it kills both pests and acari. Milbemycin oxime is a macrolide that kills parasites. It is made by fermenting products from the subspecies Streptomyces hygroscopicus. Altogether, they protect against a huge number of bugs in a single dose that dogs can chew.
Why Combination Therapy Matters in Parasite Control
It's not possible for one chemical to kill all the different kinds of parasites that a dog might come across in its daily life.Insect and spider pests, like fleas and ixodid ticks, need a drug that attacks their nerve systems. Worms that live inside of animals, like heartworm larvae (Dirofilaria immitis) and gut roundworms, need an anthelmintic that can get into their muscles and nerves. You don't need to take two different medications because Afoxolaner and milbemycin oxime chewable tablets contain both of them. It's easier to remember to take your doses this way, which directly raises safety.
How Do Afoxolaner and Milbemycin Oxime Chewable Tablets Affect Parasite Nerve Signaling?
Afoxolaner's Action on GABA-Gated Chloride Channels
Afoxolaner targets ligand-gated chloride ion channels in crustacean nerve cells, mainly those that are controlled by GABA. GABA binds to these receptors and opens chloride channels when everything is okay. This slows down nerve activity. When afoxolaner binds to the receptor, it stops this process by not letting the chloride channel open. The parasite has neuronal hyperexcitation that it can't control, which stops it from moving and kills it. It is important to note that afoxolaner binds to insect GABA receptors much more strongly than to mammalian ones. That's why fleas, ticks, and mites can't handle it as well as dogs can.
Milbemycin Oxime's Action on Glutamate-Gated Chloride Channels
Both in terms of how it is built and how it works, milbemycin oxime uses a different pathway. Nerve and muscle cells in invertebrates have chloride channels that are opened and closed by glutamate. There are no systems like these in vertebrates. Milbemycin oxime makes the membrane more permeable to chloride ions once it is bound to it. This makes the membrane more charged. The cells can't make normal action potentials anymore because they are disrupted. This makes the parasite's nerves and muscles weak and floppy. Milbemycin oxime has a hard time getting into animals' brains from their blood. This adds an extra layer of safety for dogs that are getting therapeutic amounts.
Afoxolaner and Milbemycin Oxime Chewable Tablets and Target-Specific Parasite Paralysis
External Parasites: Fleas, Ticks, and Mites
The blood level of afoxolaner is at its maximum two to four hours after it is taken by mouth. Eighty-eight percent of the body can use it, and its half-life in plasma is about two weeks. The product starts to kill fleas and ticks as soon as it is eaten because it breaks down so fast. When these outside parasites feed on dogs that have been treated, they take in afoxolaner through their blood. It quickly knocks out the dogs because it blocks GABA-gated channels. If you give the afoxolaner and milbemycin oxime chewable tablets to a cat flea, an Ixodes ricinus flea, or a Rhipicephalus sanguineus flea, within 24 to 48 hours, they work very well against all three.
Internal Parasites: Heartworm and Gastrointestinal Nematodes
Milbemycin oxime also does a great job of getting rid of parasites that live inside the body. Milbemycin A3 (20%) and A4 (80%) make it up, and each has its own metabolic properties. The highest level of milbemycin A3 is reached one to two hours after a dose, and it stays in the body for 1.6 days. Milbemycin A4 kills bugs for 3.3 days after the last dose and for a whole month after that. Heartworm disease is caused by the L3 and L4 stages of the Dirofilaria immitis larvae. It stops and treats diseases caused by Toxocara canis, Toxascaris leonina, Ancylostoma caninum, and Trichuris vulpis very well.
How Do the Two Active Ingredients Complement Each Other in Parasite Control?
Closing the Coverage Gap Between Internal and External Parasites
A lot of drugs that kill parasites only work on parasites that live inside or outside the body. Very few drugs work just as well on both. Afoxolaner and milbemycin oxime chewable tablets have molecules that are made to close that gap. For heartworm larvae and gut worms, milbemycin oxime gets into deeper systemic tissues. Afoxolaner, on the other hand, mostly works in the bloodstream and skin-level tissues where ectoparasites eat. Both chemicals can move through tissue at a rate of about 2.6 to 2.7 L/kg. This means they are widely available in the body and can reach both the outside and the inside.
Pharmacokinetic Synergy in a Monthly Dosing Schedule
Afoxolaner has a half-life of about 14 days, which means that it keeps you safe from ectoparasites for a whole month. Some drugs in the same class have longer half-lives than milbemycin oxime, but it still works and can be used once a month to get rid of heartworm larvae that can be stopped. To be killed before they grow up, these larvae need plasma amounts that stay the same. The balance in pharmacokinetics between the two active ingredients means that taking the medicine by mouth once a month makes scientific sense and works in real life.
From Parasite Receptor Binding to Paralysis: Afoxolaner and Milbemycin Oxime Chewable Tablets
The Molecular Cascade From Receptor Binding to Organism Death
Both active ingredients do their jobs by attaching to receptors, blocking channels, and either depolarizing or hyperpolarizing membranes. This stops muscles from working, makes them paralyzed, or kills them. This recipe is very useful because it has two ways that can be used separately. A bug might get used to one way of killing itself, but the other way could still kill it. This makes it less likely that two different parasites will become resistant to each other, which is a big plus for long-term methods that veterinary parasitologists recommend.
Safety Profile Rooted in Receptor Selectivity
Milbemycin oxime chewable tablets and afoxolaner are both safe for dogs that are not MDR1/ABCB1 gene mutants. This is because they are made to only attach to certain receptors. Afoxolaner binds more strongly to GABA receptors in arthropods than to those in mammals, and milbemycin oxime depends on glutamate-gated chloride channels that aren't found in vertebrates. These two things work together to make a healing window that is big enough to make sure that the drug works against bugs without being harmful to healthy adult dogs' bodies. Dogs younger than 8 weeks or lighter than 2 kg shouldn't be given this product. Also, Collies and other related breeds should talk to a vet because they may be sensitive to drugs that work with the MDR1 gene.
Conclusion
Now that you know how afoxolaner and milbemycin oxime chewable tablets work, you can see why they are the most popular way to get rid of bugs in dogs. With just one monthly dose, the blend protects completely, as proven by science. For parasites that are outside the body, it blocks GABA channels, and for parasites that are inside the body, it activates glutamate channels. There is a good safety record for both active ingredients when given once a month, and the fact that each molecule selectively targets a different receptor supports this.
Frequently Asked Questions
Q1: How do afoxolaner and milbemycin oxime chewable tablets work against different parasites?
+
-
Afoxolaner works on GABA-gated chloride channels in external parasites such as fleas, ticks and mites, while milbemycin oxime targets glutamate-gated chloride channels in interior parasites such as heartworm larvae and gastrointestinal worms. They have various systems that work together to control parasites.
Q2: How quickly do afoxolaner and milbemycin oxime chewable tablets begin to act?
+
-
In dogs, peak blood concentration of afoxolaner is achieved between 2 to 4 hours after oral treatment, but peak levels of milbemycin oxime are achieved within 1 to 2 hours. This facilitates quick response against external and internal parasites, the paper says.
Q3: Why do afoxolaner and milbemycin oxime target parasites without affecting dogs in the same way?
+
-
The article states afoxolaner has a higher affinity for GABA receptors in arthropods, whereas milbemycin oxime targets glutamate-gated chloride channels, which are not present in vertebrates. Their effect against parasites is explained by their receptor specificity.
Partner with Bloomtechz for Reliable Afoxolaner and Milbemycin Oxime Chewable Tablets Supply
This is where Bloomtechz can get a lot of afoxolaner and milbemycin oxime chewable tablets. You can get afoxolaner and milbemycin oxime chewable tablets from Bloomtechz. The plant they work out of is 100,000 square meters and is GMP-certified. It has approvals from the US FDA, the EU GMP, Japan, and the CFDA. Quality control at our company has three levels: plant inspection, in-house QA/QC review, and proof by a third-party authority. We have been making fine chemicals and pharmaceutical intermediates for over 12 years, and we promise stable product quality. Our production can be made to fit a wide range of weight needs, and OEM/ODM can be used to make changes. We are hired by people in the UK, Australia, Japan, the US, and other places. Talk to us right away, and we'll help you with your next buying cycle in a way that is correct, clear, and sure of its technical skills.
Email us at Sales@bloomtechz.com.
References
1. Beugnet, F., & Franc, M. (2012). Insecticide and acaricide molecules and/or combinations to prevent pet infestation by ectoparasites. Trends in Parasitology, 28(7), 267–279.
2. Shoop, W. L., Mrozik, H., & Fisher, M. H. (1995). Structure and activity of avermectins and milbemycins in animal health. Veterinary Parasitology, 59(2), 139–156.
3. Letendre, L., Harriman, J., Drag, M., Mullins, A., Malinski, T., & Rehbein, S. (2014). The intraparasitic mode of action of afoxolaner: sodium channel activation by afoxolaner in Ctenocephalides felis neurons. Veterinary Parasitology, 201(1–2), 18–24.
4. Prichard, R. K., & Geary, T. G. (2019). Perspectives on the utility of moxidectin and macrocyclic lactones for the control of parasitic nematodes in the face of developing anthelmintic resistance. International Journal for Parasitology: Drugs and Drug Resistance, 10, 69–83.
5. Drag, M., Angen, C., Lendel, M., & Mullins, A. (2015). Pharmacokinetic profile of afoxolaner following oral administration to dogs. Journal of Veterinary Pharmacology and Therapeutics, 38(4), 375–382.
6. Mitre, A., Lavergne, N., Crevat, D., & Bousquet-Mélou, A. (2016). Milbemycin oxime pharmacokinetics and bioavailability in dogs following oral administration of a combined chewable formulation. Veterinary Parasitology, 225, 56–62.